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Introduction {#sec1}
============

Neuroblastoma (NB) is a heterogeneous childhood tumor of the sympathetic nervous system, originating from embryonal neural crest cells ([@bib5], [@bib7]). *MYCN*-oncogene amplification is a strong clinical marker of aggressive disease and poor outcome and is present in ∼40% of high-risk cases ([@bib28], [@bib38]). Importantly, an overall elevated MYC signaling is also predictive of high-risk and stage of the disease, independently from *MYCN*-amplification ([@bib13]).

The MYCN transcription factor belongs to the MYC family of oncoproteins (comprising MYCN, c-MYC, and MYCL), whose expression is deregulated in a vast number of human cancers. MYC overexpression is functionally linked to most aspects of tumorigenesis ([@bib9], [@bib30]) and is involved in the regulation of nucleotide biosynthesis, ribosome and mitochondrial biogenesis, and other metabolic processes ([@bib31]). Furthermore, MYC-regulated proliferation is associated with enhanced activity of mitochondrial processes, and MYC inhibition decreases metabolic activity of cancer cells, leading to reduced proliferation. In addition, it has been shown that MYC overexpressing cells use both oxidative phosphorylation (OXPHOS) as well as glycolysis for energy production ([@bib33]).

Despite an increasing recognition of the importance of tumor metabolism for cancer aggressiveness and progression, still very few reports exist on the metabolic properties of *MYCN-*amplified tumors. We have previously shown that MYCN inhibition in *MYCN*-amplified neuroblastoma cells leads to accumulation of cytoplasmic lipid droplets, a phenomenon linked to mitochondrial dysfunction and inhibition of fatty acid oxidation ([@bib49]).

Here, we have characterized the consequences of central metabolic alterations in NB. To obtain a deeper understanding of the role of MYCN in regulating metabolic changes in NB cells, we downregulated *MYCN* followed by an integrated analysis combining quantitative mass spectrometry proteomics ([@bib4]) with transcriptome analysis of patient datasets ([@bib25]). Metabolic properties of neuroblastoma cells were characterized by functional assays and metabolic tracing experiments. Our findings show that *MYCN-*amplified NB cells and tumors display prominent protein and gene expression alterations in metabolic genes compared with non-*MYCN*-amplified NB, indicative of overall activated mitochondrial and glycolytic function and unexpectedly associated with glutamine synthesis. Furthermore, we found that β-oxidation of fatty acids is a major contributor to mitochondrial oxidative processes.

Collectively, we have identified a promising approach to target *MYCN*-amplified tumors by demonstrating that inhibition of fatty acid oxidation led to a reduced tumor burden in *MYCN*-amplified xenograft models, whereas not affecting non-*MYCN*-amplified tumors.

Results {#sec2}
=======

Overlap of the Protein and mRNA Profiles of *MYCN*-amplified NB Cells and Tumors Shows Dependency on the Level of MYC Signaling {#sec2.1}
-------------------------------------------------------------------------------------------------------------------------------

To identify differentially regulated metabolic pathways in *MYCN*-amplified versus non-*MYCN*-amplified tumor samples and establish the connection to a cell line model with adjustable MYCN levels, we combined information from protein levels *in vitro* with mRNA expression from patient datasets ([@bib25]). In order to explore how MYCN accounts for relevant metabolic processes, we performed high-resolution mass spectrometry quantitative proteomics following MYCN downregulation ([Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib4]; [@bib22]) in *MYCN*-amplified SK-N-BE(2) cells stably expressing a small hairpin construct against *MYCN* under the control of an inducible doxycycline promoter, BE(2)*sh MYCN* ([@bib18]). MYCN levels were either high due to the *MYCN*-amplification in untreated cells, termed "BE(2)*sh MYCN* ON" or downregulated upon treatment with doxycycline in "BE(2)*sh MYCN* OFF" cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B). In total, 6504 proteins were identified and 4779 passed initial quality controls ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Out of these, 1781 (37%) were significantly differentially up- or downregulated at a cutoff 1.4 and 0.7, respectively, in the same direction at both 24 and 48 h when comparing doxycycline-treated with nontreated BE(2)*sh MYCN* cells ([Table S1](#mmc2){ref-type="supplementary-material"}). The proteomics findings were validated using immunoblotting ([Figure S1](#mmc1){ref-type="supplementary-material"}D).

Gene Set Enrichment Analysis (GSEA) identified metabolism as one of the most affected processes in NB cells. We asked if these differences in protein levels *in vitro* relate to gene expression differences in NB patients ([Figure 1](#fig1){ref-type="fig"}). To this end, we compared metabolic proteins affected by MYCN regulation with mRNA expression data from neuroblastoma primary tumors ([@bib25]). The proteomics data show up- (in red) and downregulated (in blue) proteins upon MYCN downregulation. Notably, we observed that the protein expression pattern after MYCN downregulation *in vitro* was opposite to the mRNA expression levels of the corresponding genes in patients with *MYCN*-amplification, whereas it showed a similar pattern to that of patients with lower MYC signaling ([Figure 1](#fig1){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}). This highlights the adequacy of our *in vitro* model system to study the impact of MYCN on metabolic processes while reflecting MYCN-associated expression patterns in patients. These data suggest that *MYCN*-amplification alters key metabolic pathways as glycolysis and gluconeogenesis, fatty acid biosynthesis, citric acid cycle, mitochondrial electron transport chain, glutathione metabolism, and redox enzymes ([Figures S2--S4](#mmc1){ref-type="supplementary-material"}).Figure 1Protein and mRNA Overlap of Metabolism-Related Genes Display Dependence on MYC Signaling LevelHeatmap displaying proteins involved in metabolic processes (left) and mRNA levels of the corresponding genes in NB patients (right). Red: upregulation; blue: downregulation. MYC signaling was inferred using gene expression ([@bib13]). Top: the *MYCN*-amplified (MNA) cases were separated and the remaining samples were then subdivided into quartiles of inferred MYC signaling (Q1-4). The heatmap to the left shows changes in protein expression upon MYCN downregulation in BE(2)sh *MYCN* cells for 24 and 48 h, and the right heatmap shows the expression of the corresponding genes in 612 neuroblastoma patients ([@bib25]) divided according to MYC signaling or MNA cases as indicated.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

MYCN Levels Are Linked to Metabolic Programs and Clinical Outcome {#sec2.2}
-----------------------------------------------------------------

Analysis of gene and protein expression in BE(2)*sh MYCN* ON versus BE(2)*sh MYCN* OFF cells revealed prominent differences in the main metabolic pathways. Combined mapping of mRNA and protein expression shows altered levels of several glycolytic enzymes ([Figure S2](#mmc1){ref-type="supplementary-material"}), including hexokinase isoform 2 (HK2), which has been previously implicated in NB ([@bib24]). We next analyzed overall survival in two neuroblastoma patient cohorts with similar proportions of *MYCN*-status and patient data covering all five INSS stages ([Figure S1](#mmc1){ref-type="supplementary-material"}E; [@bib25], [@bib32]). High levels of *HK2* were correlated with poor clinical outcome ([Figures 2](#fig2){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}F) and we also observed that *HK2* expression was related to MYCN levels in NB tumors and cells ([Figures 2](#fig2){ref-type="fig"}B and 2C).Figure 2MYCN Levels Are Linked to Metabolic Programs and Clinical Outcome(A) Kaplan-Meier plot showing overall survival of NB patients based on *HK2* mRNA levels subdivided into expression quartiles (Q1-4).(B) Boxplots of *HK2* expression based on quartiles of MYC signaling and *MYCN*-amplified cases in clinical NB samples ([@bib25], [@bib13]).(C) Immunoblot showing HK2 protein expression after treatment of BE(2)sh *MYCN* cells with 2 μg/mL doxycycline as indicated. Representative blot from three independent experiments is shown; α-tubulin was used as a loading control.(D) Gene Ontology (GO) aerobic respiration and mitochondrial translation enrichment plots (using c5.bp.v5.2.symbols.gmt gene set derived from the Biological Process Ontology) in BE(2)sh *MYCN* ON vs. BE(2)sh *MYCN* OFF NB cells. Red: upregulation; blue: downregulation.(E) Kaplan-Meier overall survival curve from the Kocak cohort based on the mRNA expression of the *NRF1* gene.(F) Transmission electron microscopy images of representative mitochondria in BE(2)sh *Scramble* and BE(2)sh *MYCN* cells. Cells were treated with vehicle or 2 μg/mL doxycycline for 72 h. Scale bars indicate 1 μm.(G) Kaplan-Meier overall survival curves from the Kocak cohort based on the mRNA expression of the *MTFP1* and *OPA1* genes.See also [Figures S2--S4](#mmc1){ref-type="supplementary-material"}.

In addition, enzymes of the tricarboxylic acid cycle (TCA) and the electron transport chain (ETC) were also overexpressed in *MYCN*-amplified cells and tumors ([Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}). The enzymes citrate synthase (CS), isocitrate dehydrogenase isoform 2 (IDH2), and alpha ketoglutarate dehydrogenase-like (OGDHL) were found to have enhanced expression both at the mRNA and at the protein levels in *MYCN*-amplified cells and patients ([Figure S2](#mmc1){ref-type="supplementary-material"}). High mRNA expression of the genes encoding the majority of TCA enzymes significantly correlated to poor patient survival ([Figure S2](#mmc1){ref-type="supplementary-material"}). Importantly, we also demonstrated major alterations at the protein and mRNA levels of complexes of the ETC and in the ATP synthase ([Figure S3](#mmc1){ref-type="supplementary-material"}). Most of these respiratory subunits were upregulated in *MYCN*-amplified cells and tumors, although some subunits were also found to be downregulated. Notably, high expression of the *MYCN-*associated respiratory subunit genes correlated to poor overall survival ([Figure S3](#mmc1){ref-type="supplementary-material"}).

Gene and protein expression data showed an enhanced expression of key antioxidant-mediating enzymes in *MYCN*-amplified cells and tumors ([Figure S4](#mmc1){ref-type="supplementary-material"}). Among them were several enzymes of glutathione metabolism ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B) and of glutathione-linked ROS detoxification ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Furthermore, members of the peroxiredoxin ROS scavenger system, including peroxiredoxin 6 (PRDX6), were upregulated in *MYCN*-amplified tumors and/or cells ([Figure S4](#mmc1){ref-type="supplementary-material"}C). High mRNA expression levels of the majority of the MYCN-associated antioxidant regulating enzymes ([Figure S4](#mmc1){ref-type="supplementary-material"}C) correlated to worse prognosis and a reduced overall survival in NB patients. We investigated the impact of MYCN expression on OXPHOS in NB cells in more detail. Gene set enrichment analysis (GSEA) of the protein profile of BE(2)*sh MYCN* cells demonstrated that proteins positively regulated by MYCN were associated with aerobic respiration and mitochondrial translation processes ([Figure 2](#fig2){ref-type="fig"}D). Data analysis suggested that the majority of mitochondrial proteins are overexpressed in *MYCN*-amplified NB cells and tumors ([Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}). The gene encoding the transcription factor nuclear respiratory factor 1 (NRF1), which regulates mitochondrial biogenesis through activation of key metabolic enzymes essential for mitochondrial translation and respiration ([@bib20]), was found upregulated in *MYCN*-amplified cells and correlated to reduced survival probability in neuroblastoma patients ([Figure 2](#fig2){ref-type="fig"}E and [Table S1](#mmc1){ref-type="supplementary-material"}). We used transmission electron microscopy (TEM) to show intact mitochondrial architecture in BE(2)*sh MYCN* ON and Tet-21/N ON cells, whereas reduced electron density and an increased number of damaged *cristae* were found in the mitochondria of BE(2)*sh MYCN* OFF and of Tet-21/N OFF cells ([Figures 2](#fig2){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}I). Notably, MYCN downregulation was associated with decreased number as well as swelling of mitochondria ([Figures 2](#fig2){ref-type="fig"}F and [SF](#mmc1){ref-type="supplementary-material"}I). Members of both the mitochondrial fission as well as fusion machinery were upregulated in *MYCN*-amplified tumors and/or cells ([Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}), including optic atrophy 1 (OPA1) and mitochondrial fission process 1 (MTFP1). In addition, high mRNA expression levels of *OPA1* and *MTFP1* correlated with worse prognosis and reduced overall survival in NB patients ([Figures 2](#fig2){ref-type="fig"}G and [S1](#mmc1){ref-type="supplementary-material"}J).

Although the analysis of whether the regulation of metabolic genes occurred by direct or indirect transcriptional activity of MYCN is out of the scope of the present study, we compared the 313 metabolic proteins from our proteomics analysis shown in [Figure 1](#fig1){ref-type="fig"} with a list of direct MYCN targets in neuroblastoma cell lines previously published ([@bib19]). These authors used chromatin-immunoprecipitation (ChIP)-sequencing to identify direct MYCN target genes. We found that 45 of our proteins were present in their list of MYCN targets and importantly, that the direction of the *shMYCN* regulation of these proteins was in all cases contrary to the action of MYCN (activation/repression) these authors describe for the corresponding genes. Thus, if MYCN activates a particular gene, we observed that sh*MYCN* downregulated the corresponding protein and *vice versa* for all of these 45 proteins ([Table S3](#mmc1){ref-type="supplementary-material"}). MYCN could indirectly modify the levels of the other proteins shown in [Figure 1](#fig1){ref-type="fig"} through the plethora of transcriptional regulators controlled by this oncoprotein ([@bib19]) or by other regulatory loops. Furthermore, additional proteins affected by sh*MYCN* could be direct MYCN-targets not identified by [@bib19]. In summary, our data analysis suggests that MYCN increases expression of glycolytic and mitochondrial enzymes and highlights the importance of metabolism in mediating tumor aggressiveness in *MYCN*-amplified NB.

MYCN Increases the Glycolytic and OXPHOS Capacity of *MYCN*-amplified NB Cells {#sec2.3}
------------------------------------------------------------------------------

To investigate the functional impact of MYCN on metabolism in NB cells we employed extracellular flux-based analyses. We compared the glycolytic capacity of three cell lines in which *MYCN* expression can be regulated with doxycycline, BE(2)*sh MYCN,* Kelly *shMYCN,* and Tet-21/N ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1H), before and after MYCN downregulation, as well as of non-*MYCN*-amplified NB cells. Glycolytic parameters (basal glycolysis, glycolysis, glycolytic capacity, and glycolytic reserve) were assessed by measuring the extracellular acidification rate (ECAR) ([Figure S5](#mmc1){ref-type="supplementary-material"}A). We found that all parameters were significantly reduced after 72 h of MYCN inhibition in two different *MYCN*-amplified NB cell lines and in the Tet-21/N *MYCN*-overexpressing NB cell line ([Figures 3](#fig3){ref-type="fig"}A and 3B). Examination of the ECAR in the non-*MYCN*-amplified SH-EP, SK-N-SH, and SK-N-AS NB cell lines revealed reduced ECAR for all glycolytic parameters in comparison with BE(2)*sh MYCN* cells ([Figure 3](#fig3){ref-type="fig"}A). Taken together, our results demonstrate that *MYCN*-amplification is associated with enhanced glycolytic activity in NB.Figure 3MYCN Increases the Glycolytic and OXPHOS Capacity of *MYCN*-amplified NB Cells(A) Quantification of extracellular acidification rate (ECAR) in BE(2)sh *MYCN* ON, BE(2)sh *MYCN* OFF, SK-N-SH, SH-EP, and SK-N-AS cells.(B) Quantification of ECAR levels in Kelly sh*MYCN* and Tet-21/N cells before and after regulation of MYCN expression as indicated.(C) Quantification of oxygen consumption rate (OCR) in BE(2)sh *MYCN* ON, BE(2)sh *MYCN* OFF, SK-N-SH, SH-EP, and SK-N-AS cells.(D) Quantification of OCR levels in Kelly sh*MYCN* and Tet-21/N cells before and after regulation of MYCN expression as indicated.(E) Baseline and stressed phenotype (open and filled circles, respectively) of BE(2)sh *MYCN* before and after downregulation of MYCN expression, SK-N-SH, and SH-EP cells, as indicated.(F) Visualization of the increase of metabolic potential in the experiments shown in (E).All data are presented as the mean ± SD of three independent experiments performed at 72 h of MYCN regulation, with ^∗^, ^∗∗^, ^∗∗∗^ indicating p \< 0.05, p \< 0.01 and p \< 0.001, respectively.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Next, we analyzed key parameters of respiration in several *MYCN*-amplified and non-*MYCN-*amplified NB cells by measuring the oxygen consumption rate (OCR) ([Figure S5](#mmc1){ref-type="supplementary-material"}B): basal, ATP-coupled, maximal/uncoupled respiration, as well as the spare/reserve respiration. Our analysis showed that *MYCN*-amplified NB cells and MYCN-overexpressing Tet-21/N cells displayed increased OCR levels compared with non-*MYCN*-amplified NB and cells with MYCN downregulation ([Figures 3](#fig3){ref-type="fig"}C and 3D). Both basal and maximal respiration were significantly higher in BE(2)*sh MYCN* ON cells compared with cells after 72 h of MYCN downregulation (BE(2)*sh MYCN* OFF) or non-*MYCN*-amplified NB cells ([Figures 3](#fig3){ref-type="fig"}C and 3D). In addition, ATP-coupled and increased uncoupled respiration indicated that MYCN expression promotes energy production via oxidative phosphorylation. Together, gene expression and functional assays demonstrate that MYCN positively regulates mitochondrial respiration in *MYCN*-amplified NB cells.

To evaluate the ability of the cells to regulate both glycolytic flux and mitochondrial respiration as a response to induced metabolic stress, we used the ATP synthase inhibitor oligomycin and the mitochondrial uncoupler FCCP, respectively ([Figure 3](#fig3){ref-type="fig"}E). Inhibition of ATP synthase forced all cell lines to increase the glycolysis rate to compensate for the lack of mitochondrial energy production to a similar extent, independently of their *MYCN* status ([Figure 3](#fig3){ref-type="fig"}F). Uncoupling of ETC by FCCP increased mitochondrial respiration to maximum levels. Although all cells increased OXPHOS upon uncoupling, the elevation was significantly higher in BE(2)*sh MYCN* ON cells in comparison to *MYCN* OFF, SH-EP, and SK-N-SH cells ([Figure 3](#fig3){ref-type="fig"}F). In conclusion, we found that the stressed phenotype of the BE(2)*sh MYCN* ON cells was characterized by a shift in the metabolic balance toward robustly increased oxidative phosphorylation as well as enhanced aerobic glycolysis. In contrast, BE(2)*sh MYCN* OFF, SH-EP, and SK-N-SH cells increased glycolysis in a similar range but were not able to generate such a strong OXPHOS stress response.

Contribution of Glucose, Glutamine, and Fatty Acids to OXPHOS {#sec2.4}
-------------------------------------------------------------

The obtained results indicated that *MYCN*-amplified NB cells are characterized by both enhanced glycolysis and mitochondrial respiration. We next analyzed the contribution of the three crucial mitochondrial fuels---glucose, glutamine, and fatty acids. We measured OCR in the presence or absence of specific inhibitors of the corresponding oxidation pathways. We used UK5099, an inhibitor of the mitochondrial pyruvate transporter (MPT), to evaluate the impact of glucose on respiration, whereas the fatty acid oxidation pathway was inhibited by etomoxir, which inhibits carnitine palmitoyltransferase 1 (CPT1C), the rate-limiting enzyme of β-oxidation. To determinate glutamine oxidation we employed the kidney-type glutaminase 1 (GLS1) inhibitor BPTES. The decreased respiration in response to inhibition of the oxidation pathways determinates the capacity of the cells to oxidize a particular fuel. We found that approximately 65% of the mitochondrial respiratory capacity in *MYCN*-amplified NB cells was dependent on fatty acid oxidation (FAO) ([Figures 4](#fig4){ref-type="fig"}A, 4B, [S5](#mmc1){ref-type="supplementary-material"}C, and S5D). Surprisingly, our results demonstrated glutamine independence of mitochondrial respiration in *MYCN*-amplified NB cells compared with non-*MYCN*-amplified NB and *MYCN* OFF cells ([Figures 4](#fig4){ref-type="fig"}A and 4B). Thus, our data suggest that fatty acids are an important fuel for mitochondrial respiration in NB cells. Indeed, mitochondrial oxidation of glutamine was significantly lower than oxidation of fatty acids and/or glucose in *MYCN*-amplified NB cells. Furthermore, the ability to oxidize glutamine was increased in BE(2)*sh MYCN* OFF cells compared with BE(2)*sh MYCN* ON cells. In addition, oxidation of glutamine was also higher in SH-EP non-*MYCN-*amplified cells than in BE(2)*sh MYCN* ON cells or in Neuro-2A mouse neuroblastoma cells, and similar to the BE(2)*sh MYCN* OFF cells ([Figures 4](#fig4){ref-type="fig"}A and 4B). Since glutamine is a substrate commonly oxidized in cultured cells, the low glutamine oxidation in BE(2)s*h MYCN* ON NB cells was unexpected. To evaluate the impact of glucose and glutamine on cell survival we determined the viability of *MYCN*-amplified NB cells upon starvation conditions. Five days of glucose deprivation resulted in 90% reduction of viable BE(2)*sh MYCN* ON, SK-N-BE(2), and Tet-21/N cells. In contrast, glutamine withdrawal alone reduced cell viability only by 30% compared with complete medium conditions, and *MYCN*-amplified NB cells demonstrated glutamine independent proliferation after an initial adaptation time ([Figures 4](#fig4){ref-type="fig"}C and 4D). Taken together, our results highlight a low glutamine oxidation rate and only a small impact of glutamine starvation in highly proliferative *MYCN*-amplified NB cells.Figure 4Relative Contribution of Glucose, Glutamine, and Fatty Acids to OXPHOS(A) Quantification of OCR in BE(2)sh *MYCN* cells before and after downregulation of MYCN for 72 h and in SH-EP cells as indicated. FA = fatty acids, GLC = glucose, GLN = glutamine.(B) Quantification of OCR in Neuro-2A mouse neuroblastoma cells.(C) WST-1 assay showing percentage of viable BE(2)sh *MYCN* ON and Tet-21/N ON cells after five days in substrate-restricted medium as indicated.(D) Number of viable SK-N-BE(2) cells during five days in substrate-limited conditions determined by cell counting at the indicated time points.All data are presented as mean ± SD from three independent experiments, with ^∗^, ^∗∗^, ^∗∗∗^, ^∗∗∗∗^ indicating p \< 0.05, p \< 0.01, p \< 0.001 and p \< 0.0001, respectively.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Neuroblastoma Cells Are Able to Synthesize Glutamine {#sec2.5}
----------------------------------------------------

As mentioned above, when we compared the ability of NB cells to oxidize glucose, glutamine and fatty acids, we found that *MYCN-*amplified NB cells display reduced glutamine oxidation and the ability to survive glutamine starvation. To further investigate this phenotype, we performed isotope tracing experiments with U-^13^C~6~-glucose and U-^13^C~5~-glutamine, respectively. In BE(2)*sh MYCN* ON cells, glucose was a major source of TCA cycle carbon, because U-^13^C~6~-glucose cultures exhibited 55% ^13^C enrichment of citrate, with a prominent ^13^C~2~ mass isotopomer ([Figure 5](#fig5){ref-type="fig"}A), and 64% of acetyl-CoA, mainly as ^13^C~2~ ([Figure 5](#fig5){ref-type="fig"}B), whereas U-^13^C~5~-glutamine gave only 4% ^13^C enrichment in α-ketoglutarate, mostly as ^13^C~5~ ([Figure 5](#fig5){ref-type="fig"}C). After MYCN inhibition, the glucose contribution to citrate and acetyl-CoA diminished somewhat ([Figures 5](#fig5){ref-type="fig"}A and 5B), whereas glutamine contribution to α-ketoglutarate and citrate increased markedly ([Figures 5](#fig5){ref-type="fig"}A--5C), suggesting a switch toward oxidation of glutamine, presumably by activation of glutaminase. In addition, the contribution of glucose to other intermediates of the Krebs cycle decreased in *MYCN* OFF cells as well ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). In both conditions, about one-third of TCA cycle carbons were derived from an unknown (^12^C) source, potentially fatty acids.Figure 5*MYCN*-amplified NB Cells Exhibit *De Novo* Glutamine Synthesis Pattern(A--D) The contribution of glucose and glutamine toward TCA-cycle metabolites was measured by metabolic tracing using U-^13^C~6~-glucose or U-^13^C~5~-glutamine in BE(2)sh *MYCN* cells as indicated. Comparison of mass isotopologue distributions (MID) of citrate (A), acetyl-CoA (B), α-ketoglutarate (C), and glutamine (D) in BE(2)sh *MYCN* ON and in BE(2)sh *MYCN* OFF cells after five days of MYCN downregulation with 2 μg/mL doxycycline. MI of labeled carbons as indicated (M0-M6).See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

We noted that most of the intracellular glutamine was not labeled from U-^13^C~5~-glutamine in BE(2)*sh MYCN* ON cells, suggesting that it was not derived from uptake from the medium. Instead, we found that a majority of the cellular glutamine was synthesized from glucose via α-ketoglutarate ([Figures 5](#fig5){ref-type="fig"}C and 5D). At this time point, the medium glutamine concentration was ∼1 mM, showing that this phenomenon was not due to the exhaustion of glutamine. In contrast, in BE(2)*sh MYCN* OFF cells, there was almost no glutamine synthesis, and instead most of the glutamine was derived from the medium ([Figure 5](#fig5){ref-type="fig"}D). Such glutamine synthesis pattern is uncommon in cancer cells. To support our findings, we performed tracing experiments with both U-^13^C~5~-glucose and U-^13^C~5~-glutamine in two different *MYCN*-amplified or overexpressing cell lines where we inhibited MYCN using the small chemical MYC/MYCN-inhibitor 10058-F4 ([@bib34]) or by doxycycline. In SK-N-BE(2) cells, we obtained ∼60% ^13^C~5~ glutamine, indicating that the major part of glutamine carbons was derived from medium glutamine, but we also observed ^13^C~2~, ^13^C~3,~ and ^13^C~4~ mass isotopomers ([Figure S6](#mmc1){ref-type="supplementary-material"}C), suggesting glutamine synthesis from glucose. In Tet-21/N cells, most glutamine appeared to be synthesized from glucose ([Figure S6](#mmc1){ref-type="supplementary-material"}D), similar to BE(2)*sh MYCN* cells. In both cell lines, MYCN inhibition prevented *de novo* synthesis of glutamine. The lack of glutamine synthesis in *MYCN* OFF cells was likely mediated by inhibition of glutamate-ammonia ligase, because glutamate remained labeled from U-^13^C~6~-glucose in BE(2)*sh MYCN* OFF cells ([Figure S6](#mmc1){ref-type="supplementary-material"}E). In neither condition was glutamine converted to lactate ("glutaminolysis") ([Figure S6](#mmc1){ref-type="supplementary-material"}F).

Fatty Acid β-oxidation in *MYCN*-amplified NB Cells {#sec2.6}
---------------------------------------------------

The above results show that fatty acids greatly contribute to OXPHOS in *MYCN*-amplified cells ([Figures 4](#fig4){ref-type="fig"}A, 4B, [S5](#mmc1){ref-type="supplementary-material"}C, and S5D), and a more detailed analysis of gene and protein data confirmed that *MYCN-*amplification was indeed linked to the expression of enzymes involved in FAO ([Figures 6](#fig6){ref-type="fig"}A and 6B). Specifically, we found that high expression of the genes encoding the enzymes involved in regulating the last key steps of FAO, including *hydroxyacyl-CoA dehydrogenase* (*HADH*), was associated with adverse outcome in neuroblastoma ([Figure 6](#fig6){ref-type="fig"}A).Figure 6Fatty Acid β-oxidation in *MYCN*-amplified NB Cells(A) Schematic picture showing significantly regulated mRNAs and proteins involved in β-oxidation of fatty acids, based on KEGG pathway maps. Red and blue colors represent up- and downregulated mRNAs (ovals) in *MYCN*-amplified versus non-*MYCN* amplified tumors, or proteins (rectangles) in BE(2)sh *MYCN* ON versus BE(2) sh *MYCN* OFF cells. The correlation of expression of different genes (high or low) to patient survival using the Oberthuer patient dataset ([@bib50]) is indicated. ns= not statistically significant.(B) Gene ontology fatty acid β-oxidation enrichment plot (using c5.bp.v5.2.symbols.gmt gene set derived from the Biological Process Ontology) in BE(2)sh *MYCN* ON versus BE(2)sh *MYCN* OFF cells.(C) Left graph shows quantification of basal OCR in BE(2)sh *MYCN* and SH-EP cells. Right graph shows quantification of maximal OCR (in response to 2 μM FCCP) in the same cells.All data are presented as the mean ± SD of three independent experiments, with ^∗^, ^∗∗^, ^∗∗∗^, ^∗∗∗∗^ indicating p \< 0.05, p \< 0.01, p \< 0.001 and p \< 0.0001, respectively.

To functionally assess the impact of MYCN expression on FAO, we measured OCR in the presence of BSA-coupled palmitate as an exogenous source of fatty acids, and compared with unconjugated BSA as control. Interestingly, MYCN positively regulated the capacity for FAO, because addition of palmitate resulted in a dramatic increase in both basal and maximal respiration rate in the BE(2)*sh MYCN* ON compared with BE(2)*sh MYCN* OFF and SH-EP non-*MYCN*-amplified cells ([Figure 6](#fig6){ref-type="fig"}C). These results suggest that MYCN increases the capacity to oxidize exogenous fatty acids. In contrast, all parameters of mitochondrial respiration remained low in non-*MYCN-*amplified NB cells.

Inhibition of Fatty Acid β-oxidation in *MYCN*-amplified NB Cells Reduces Tumor Burden {#sec2.7}
--------------------------------------------------------------------------------------

Our results showed that the metabolic phenotype of *MYCN*-amplified NB cells is characterized by high rates of OXPHOS. In addition, we found that fatty acids greatly contribute to mitochondrial respiration in *MYCN-*amplified NB cells. Analysis of the Kocak ([@bib25]) and Versteeg ([@bib32]) datasets demonstrated a robust correlation between high expression of the gene encoding the rate-limiting enzyme of FAO, *CPT1C*, with poor prognosis in NB patients ([Figures 7](#fig7){ref-type="fig"}A and [S7](#mmc1){ref-type="supplementary-material"}A), suggesting that CPT1 could be an attractive treatment target. To study the effect of FAO inhibition in NB, we treated SK-N-BE(2), SH-EP, and SK-N-AS cells with two different CPT1 inhibitors, etomoxir and teglicar. We observed that the viability of SK-N-BE(2) cells was significantly reduced after seven days with etomoxir or teglicar treatment compared with nontreated cells. In contrast, inhibition of β-oxidation did not have any effect on SH-EP or SK-N-AS cells, suggesting that *MYCN*-amplified cells are more dependent on the FAO pathway ([Figures 7](#fig7){ref-type="fig"}B and [S7](#mmc1){ref-type="supplementary-material"}B). We also found that treatment with both compounds resulted in the accumulation of lipid droplets ([Figure S7](#mmc1){ref-type="supplementary-material"}F) according to our previous data on etomoxir ([@bib49]). In addition, delipidized FBS significantly reduced the number of alive SK-N-BE(2) cells compared with cells in complete FBS, whereas SH-EP cells cultured under the same conditions were less sensitive to the reduction of available lipids in the medium ([Figure 7](#fig7){ref-type="fig"}C). Furthermore, we found a significant decrease in size of soft agar colonies formed by SK-N-BE(2) cells upon etomoxir treatment ([Figure 7](#fig7){ref-type="fig"}D) and a robust reduction in colony number by teglicar ([Figure S7](#mmc1){ref-type="supplementary-material"}C). In addition, we observed that inhibition of β-oxidation in tumor spheres derived from tumors from the *TH-MYCN* mouse model resulted in increased expression of the neural differentiation marker tyrosine hydroxylase (TH) ([Figure 7](#fig7){ref-type="fig"}E). Together our results indicate the importance of FAO for *MYCN-*amplified NB proliferation and survival. Next, we analyzed the therapeutic effect of FAO inhibition *in vivo* using two different *MYCN-*amplified NB cell lines. Nude mice were subcutaneously injected with SK-N-BE(2) or IMR32 cells followed by etomoxir treatment. From day five onwards, we detected a significant decrease in tumor volume index in the treated mice compared with control animals in both experiments ([Figures 7](#fig7){ref-type="fig"}F \[left panel\] and [S7](#mmc1){ref-type="supplementary-material"}D). This result was verified by analysis of tumor weight at endpoint ([Figure 7](#fig7){ref-type="fig"}G). Staining of the tumors derived from the *in vivo* experiment demonstrated decreased expression of MYCN, the proliferation marker Ki67, as well as the master regulator of hypoxia signaling, HIF1α, upon etomoxir treatment ([Figure 7](#fig7){ref-type="fig"}H). To analyze any selective effect of CPT-1 inhibition on *MYCN*-amplified neuroblastoma tumors we next conducted an *in vivo* study using non-*MYCN*-amplified cells. Nude mice were injected with SK-N-AS cells followed by etomoxir injection. In contrast to the results obtained using SK-N-BE(2) and IMR32 cells, six days of etomoxir treatment did not have any effect on tumor volume index and/or tumor weight of the SK-N-AS tumors ([Figure 7](#fig7){ref-type="fig"}F \[right panel\] and [Figure 7](#fig7){ref-type="fig"}I). Staining of the SK-N-AS tumors showed that etomoxir treatment did not impact expression of any of the proteins analyzed ([Figure S7](#mmc1){ref-type="supplementary-material"}G). Together, our data demonstrate that NB cells are differentially sensitive to FAO inhibition depending on their MYCN status.Figure 7Inhibition of Fatty Acid β-oxidation Reduces Tumor Burden(A) Kaplan-Meier overall survival curve for the Kocak cohort based on *CPT1C* mRNA expression quartiles (Q1--4).(B) Percentage of viable cells as determined by WST-1 assay after seven days of etomoxir treatment in SK-N-BE(2), SH-EP, and SK-N-AS cells.(C) Percentage of viable SK-N-BE(2) and SH-EP cells after five days of culturing in substrate-restricted medium as determined by cell counting. All data in B and C are presented as mean ± SD from three independent experiments. MNA = *MYCN*-amplified; NMNA = non-*MYCN*-amplified.(D) Soft agar assay of SK-N-BE(2) after ten days of DMSO or 50 μM etomoxir treatment. Representative images from three independent experiments are shown to the left. Quantification of colony size was performed using OpenCFU software, shown to the right.(E) Immunoblot showing tyrosine hydroxylase (TH) expression after treatment of TH-*MYCN* tumor spheres with etomoxir as indicated. Representative blot from three independent experiments is shown. β-actin was used as loading control.(F) Tumor volume index (TVI) in xenograft models of SK-N-BE(2) (left panel) and SK-N-AS (right panel) NB cells. NMRI nude mice were treated daily with vehicle (10% β-cyclodextrin) or 20 mg/kg etomoxir. SK-N-BE(2) xenograft: n = 6 for the vehicle group and n = 5 for the etomoxir group, SK-N-AS xenograft: n = 5 for the vehicle group and n = 5 for the etomoxir group. All data are presented as mean ± SD.(G) SK-N-BE(2) xenograft tumor weights at endpoint. n = 6 for the vehicle group and n = 5 for the etomoxir group. All data are presented as mean ± SD.(H) Microscopic images of IHC staining of *in vivo* derived tumors labeled with anti-Ki67, anti-MYCN, and anti-HIF1α antibodies. Representative images from six vehicle and five etomoxir treated SK-N-BE(2) xenograft tumors are shown. Scales bars indicate 50 μm.(I) SK-N-AS xenograft tumor weights at endpoint. n = 5 for the vehicle group and n = 5 for the etomoxir group.All data are presented as mean ± SD, with ^∗^, ^∗∗^ indicating p \< 0.05 and p \< 0.01, respectively.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

During tumor progression, cancer cells need to adjust their metabolic activity in order to maintain high biosynthetic rates needed for rapid cell growth, despite conditions of low nutrient and oxygen availability, and these adaptations are crucial for cancer cell survival. This metabolic rewiring guarantees a rapid energy supply in the form of ATP and a stable source of intermediary metabolites and reducing equivalents needed for the synthesis of new biomass and the control of redox homeostasis ([@bib11]). The relevance of metabolic alterations for tumor biology has resulted in numerous clinical trials based on agents targeting tumor metabolism that have been initiated during the last decade ([@bib27]). Some of them have already been approved for the treatment of specific tumor types, including the mTOR inhibitor Everolimus for the treatment of metastatic renal cell carcinoma ([@bib39]). The proliferation rate of several malignances requires high glucose level and may be sensitive to inhibition of glucose transporters ([@bib16]). The combination of antioxidants or ROS-modulating agents with chemotherapy results in increased efficacy of treatment of patients with neck and head cancer ([@bib23], [@bib41]). However, very little is known regarding the metabolic features of *MYCN*-amplified tumors, and, specifically, neuroblastoma. Furthermore, to directly target the transcriptional activity of MYC proteins continues to be a major challenge ([@bib10]). Therefore, targeting processes downstream of MYCN could represent a successful approach to inhibit MYCN-driven malignancies. Understanding how MYCN alters the metabolic properties of NB could help to develop novel therapeutic strategies. To explore possible clinical applications of targeting metabolic processes in *MYCN-*amplified NB requires an accurate and detailed picture of possible metabolic aberrations. Here, we have used the combined information from mRNA and protein expression data, placed into a biological context when integrated with functional analysis, to depict the main metabolic features of this disease. We show that MYCN correlates with metabolic gene and protein expression programs in NB and that MYCN functionally affects major aspects of cell metabolism in NB cells.

Notably, the overlay between proteins and mRNAs not only revealed an overlap between *in vitro* and patient data but also displayed dependency on MYC signaling level. This detailed overview of the MYCN-associated metabolic processes in NB, based on the analysis of gene and protein expression data, allowed us to expose that *MYCN*-amplified cells and tumors display enhanced expression of proteins and genes involved in glycolysis, OXPHOS, and ROS detoxification. These data provide important clues of the metabolism in *MYCN-*amplified tumors that could be exploited for the development of therapeutic approaches.

An increased glycolytic flux is a characteristic feature of most cancers and is advantageous mainly because it provides energy during conditions of low oxygen levels and for the generation of chemical building blocks needed for anabolic processes used by cancer cells ([@bib11]). Although previous reports have suggested NB cells and tumors to highly depend on glycolysis for survival and malignancy ([@bib26], [@bib29]), here we could demonstrate for the first time that MYCN enhances OXPHOS in NB cells. It is generally believed that metabolic remodeling is a dynamic process that varies depending on the stage of tumorigenesis ([@bib11]). In this regard, although glycolysis activation is a hallmark of many tumors, there is an increasing appreciation of the importance of mitochondria for cancer cell survival, including the oxidation of substrates such as glucose, glutamine, and fatty acids. In fact, under some circumstances during the tumorigenic process, neoplastic cells may be critically dependent on mitochondria and oxidative phosphorylation rather than on glycolysis ([@bib43]). There is also evidence for tumors with the capacity to switch between glycolytic and oxidative metabolism under conditions of limiting substrate accessibility, and in response to hypoxia ([@bib11]). As other tumorigenic events, this metabolic adaptation is likely to be a consequence of the actions of oncogenes and tumor suppressors ([@bib35]).

Here we show that neuroblastoma cells rely both on glycolysis and OXPHOS for energy production, but the metabolic program driven by *MYCN*-amplification seems to depend to a greater extent on OXPHOS. Both OXPHOS capacity and glycolytic rate are significantly reduced following MYCN downregulation in NB cells and are lower in non-*MYCN*-amplified cells compared with amplified, showing that both pathways are positively associated to MYCN expression. However, simulation of energy demand condition demonstrates the ability of *MYCN*-amplified cells to increase OXPHOS-dependent ATP production to a greater extent than non-amplified cells. On the contrary, glycolytic parameters are MYCN independent upon stress, as both *MYCN*-amplified and nonamplified cell lines increased glycolysis to a similar extent. Of importance for possible therapeutic interventions, the analysis of patient gene expression data and proteomics results shows that high MYCN levels are associated with elevated expression of key enzymes involved in glycolysis and the citric acid cycle and with alterations in the levels of respiratory chain proteins. High expression of a vast majority of the corresponding genes correlates to poor survival of NB patients. We analyzed the impact of the expression levels of specific metabolic genes on neuroblastoma patient survival using the Kocak cohort ([@bib25]), one of the biggest publicly available neuroblastoma datasets covering gene expression data for 649 patients from all five INSS stages of the disease. We validated the results using a second independent dataset ([@bib32]) with a similar proportion of *MYCN*-amplified and non-*MYCN*-amplified patients as the Kocak cohort and with patient data from the five INSS stages. Our results suggest that targeting these enzymes or pathways could provide therapeutic opportunities for neuroblastoma treatment not explored to date.

Additionally, increasing evidence show that selection of alterations that cause escape from oxidative damage is an important mechanism of metabolic adaptation in tumors ([@bib40]) ([@bib17]) and has been linked to chemotherapy resistance in cancer stem cells ([@bib12]). Among the different functional mitochondrial protein categories and gene programs in our data were enzymes involved in ROS detoxification, including members of the peroxiredoxin system and those regulating cellular GSH levels. *MYCN-*amplified tumors are likely to have higher energy demand due to increased proliferation rate. Thus, they may compensate the increased ROS production due to increased OXPHOS by upregulation of these ROS detoxication systems required for cell survival.

Fatty acids, glucose, and glutamine are crucial substrates for Krebs cycle function and mitochondrial energy production in many cancer types ([@bib3]). In fact, nutrient dependency is recognized as a feature of MYC-transformed tumors ([@bib9]). Several studies have demonstrated glutamine addiction of cancer cells driven by MYC ([@bib44], [@bib45]), although MYC is also able to induce glutamine synthesis in a mouse model of NSCLC ([@bib47]). Here we demonstrate that neuroblastoma cells are able to fuel oxidative metabolism using different substrates, with fatty acids and glucose as the major sources, and with limited contribution of glutamine in *MYCN*-amplified cells. Importantly, these cells are able to perform *de novo* glutamine synthesis based on metabolic tracing experiments showing uptake of U-^13^C~6~-glucose for glutamine synthesis in *MYCN*-amplified cells. In spite of glutamine being the most abundant amino acid in plasma ([@bib42]), intra-tumoral availability of glutamine might be restricted due to limited vascularization and nutrient diffusion. Notably*, MYCN*-amplified cells are able to survive glutamine starvation and even support cell growth after an initial period of adaptation. Our data may explain the adaptability and high aggressiveness of MYCN-driven tumors and provide new information about neuroblastoma biology.

As mentioned above, both glucose and fatty acids are the major substrates for OXPHOS in *MYCN*-amplified neuroblastoma cells. Previous studies have determined the feasibility of targeting glucose utilization as a strategy to treat neuroblastoma ([@bib1]). Since no previous reports have approached the impact of lipid catabolism in neuroblastoma, here we characterized the therapeutic potential of interfering with fatty acid oxidation in this tumor. Stimulation of FAO can provide a mechanism for survival in the absence of glucose by contributing to cytosolic NADPH levels and ATP supply by OXPHOS ([@bib2], [@bib6]). We found that MYCN is linked to multiple changes in the mRNA and protein expression levels of β-oxidation--associated enzymes. Acyl-CoA dehydrogenases (ACADSs) are involved in regulating the first step of fatty acid oxidation. Importantly, protein expression of ACADSs were found to correlate inversely to NB patient survival, whereas those enzymes regulating the last key steps of β-oxidation (3-hydroxyacyl-CoA dehydrogenases \[HADH\] and 3-ketoacyl thiolase \[ACAA2\]) correlate with poor outcome when highly expressed ([Figure 6](#fig6){ref-type="fig"}A). High expression of gene encoding the β-oxidation rate-limiting enzyme CPT-1 also correlates with poor prognosis in NB patients. Hence, based on these observations, the picture of a potential role of β--oxidation in *MYCN*-amplified NB is not clear-cut. However, our results strongly suggest that fatty acids are a major substrate for OXPHOS-based energy metabolism in NB. Interestingly, we found that MYCN positively regulates the capacity for oxidizing exogenous fatty acids in NB cells. Furthermore, we showed that reduced availability of extracellular lipids, without any chemical intervention, diminished neuroblastoma cell viability *in vitro*. Together these findings reflect the overall induced OXPHOS capacity of *MYCN*-amplified NB cells, which includes the ability of oxidizing fatty acids. Accordingly, the CPT-1 small molecule inhibitors etomoxir and teglicar were able to reduce *MYCN*-amplified neuroblastoma cell viability and colony formation. Although etomoxir, an irreversible CPT1 inhibitor, has been described to be able to inhibit mitochondrial complex I, this occurs at concentrations much higher than those used in the present study ([@bib46]). Etomoxir reached Phase II clinical trials as an antidiabetic agent before being discontinued due to hepatic toxicity but continues to be widely used as a tool to study FAO in preclinical studies. Teglicar is a recently developed selective and reversible CPT1 inhibitor that also shows antidiabetic activity ([@bib8]). This molecule does not share a similar toxicity profile as etomoxir. While we and others have previously used etomoxir as a tool to inhibit FAO in neuroblastoma cells *in vitro* ([@bib49], [@bib36], [@bib48]), we show here for the first time that this FAO-inhibitor is able to reduce *MYCN*-amplified xenograft tumor growth *in vivo*. Importantly, we demonstrate that non-*MYCN*-amplified neuroblastoma tumor growth was not affected by FAO-inhibition, thus showing specificity for *MYCN*-amplification. In this respect it is intersting that β-oxidation of exogenous fatty acids delivered by nearby adipocytes to ovarian cancer cells was shown to be an important mechanism for tumor metastasis and rapid tumor growth ([@bib37]). The outcome of our *in vivo* study demonstrated the therapeutic potential of FAO inhibition in *MYCN*-amplified NB and suggests that this approach may be used as a basis for the development of novel therapeutic strategies for *MYCN*-amplified NB patients.

Together our data indicate that MYCN facilitates a high-energetic metabolic phenotype in NB, pointing to the possibility that tumors with elevated MYCN signaling have a greater ability than the nonamplified tumors to use different metabolic strategies during tumor progression, depending on microenvironmental and intratumoral nutrient availability and level of metabolic stresses ([@bib21]). Our work highlights several pathways as critical for the aggressive clinical behavior of *MYCN*-amplified NB tumors. This information can be used to further investigate the importance of these regulatory metabolic networks for *MYCN*-amplified NB cell survival and as a basis for the development of novel therapies.

Limitations of the Study {#sec3.1}
------------------------

In this study, we performed *in vitro* experiments using the CPT1C inhibitors etomoxir and teglicar, whereas the *in vivo* experiments were limited to etomoxir. As mentioned in the discussion, etomoxir was discontinued from clinical trials due to toxicity and has, at higher concentrations than we employed, unspecific targets such as complex I of the electron transport chain. Future *in vivo* studies with additional CPT1C inhibitors, including teglicar, remain to be performed. Notably, the neuroblastoma cell lines used in our xenograft experiments are highly aggressive and develop tumors rapidly, allowing for a very short therapeutic window of only 7--8 days. Therefore, it may be of importance to use the transgenic TH*-MYCN* mouse neuroblastoma model in future experiments.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods, Figures S1--S7, and Table S3Table S1. Proteins Differently Expressed in BE(2)*sh MYCN* Cells in Response to Doxycycline Treatment (2 μg/mL) Using Cutoff Ratios of 0.7 and 1.4 for Down- and Upregulated Proteins, Respectively, Related to Figures 1 and S1Table S2. Proteins Differently Expressed in BE(2)*sh MYCN* Cells in Response to Doxycycline Treatment (2 μg/mL) and Similarly Regulated at mRNA Level in the Kocak Patient Cohort, Related to Figure 1 and Figure S1Protein expression data from Figure S1 was compared to gene expression differences in the Kocak neuroblastoma patient dataset.
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